Aptinyx’s Chronic Pain Candidate Fails To Top Placebo In Mid-Stage Study
Aptinyx Inc (NASDAQ: APTX) has announced results from a Phase 2b study evaluating the effects of NYX-2925 in patients with fibromyalgia, characterized by muscular or musculoskeletal pain with stiffness and localized tenderness at specific points.